共 200 条
- [21] Nishiwaki N(2019)Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis J Cachexia Sarcopenia Muscle 10 1165-2409
- [22] Furukawa K(2022)Association between sarcopenia and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis Front Nutr 9 978110-1336
- [23] Omori H(2021)Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil BMC Cancer 21 1219-243
- [24] Kaji S(2022)Pre-treatment CRP and albumin determines prognosis for unresectable advanced oesophageal cancer In Vivo 36 1930-645
- [25] Digklia A(2017)Chemotherapy for advanced gastric cancer Cochrane Database Syst Rev 8 Cd004064-139
- [26] Wagner AD(2022)Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 23 234-undefined
- [27] Janjigian YY(2018)Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis Cancer Chemother Pharmacol 81 981-undefined
- [28] Shitara K(2017)Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 390 2461-undefined
- [29] Moehler M(2018)Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 19 1437-undefined
- [30] Garrido M(2015)Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer Ann Oncol 26 141-undefined